| Literature DB >> 35544437 |
Patricia Zhu1,2, Ovidiu Tatar1,3, Gabrielle Griffin-Mathieu1, Samara Perez4,5, Ben Haward1, Gregory Zimet6, Matthew Tunis7, Ève Dubé8, Zeev Rosberger1,2,5,9.
Abstract
BACKGROUND: High COVID-19 vaccine uptake is crucial to containing the pandemic and reducing hospitalizations and deaths. Younger adults (aged 20-39 years) have demonstrated lower levels of vaccine uptake compared to older adults, while being more likely to transmit the virus due to a higher number of social contacts. Consequently, this age group has been identified by public health authorities as a key target for vaccine uptake. Previous research has demonstrated that altruistic messaging and motivation is associated with vaccine acceptance.Entities:
Keywords: COVID-19; altruism; digital health; digital intervention; health information; health intervention; health promotion; online health; prosocial motives; public health; randomized controlled trial; vaccination; vaccine hesitancy; video intervention; web survey; younger adults; youth
Mesh:
Substances:
Year: 2022 PMID: 35544437 PMCID: PMC9153910 DOI: 10.2196/37328
Source DB: PubMed Journal: JMIR Public Health Surveill ISSN: 2369-2960
Figure 1CONSORT diagram. CONSORT: Consolidated Standards of Reporting Trials; PAPM: Precaution Adoption Process Model.
Sociodemographic variables.
| Characteristics | Total (N=1373) | Video group (N=686) | Text group (N=687) | Between-group differencea
| ||
| Age, mean (SD) | 30.7 (5.3) | 30.7 (5.4) | 30.7 (5.3) | .94 | ||
|
| .98 | |||||
|
| Male | 633 (46.1) | 316 (46.1) | 317 (46.1) | —b | |
|
| Female | 740 (53.9) | 370 (53.9) | 370 (53.9) | — | |
|
| .98 | |||||
|
| Man | 626 (45.6) | 311 (45.3) | 315 (45.9) | — | |
|
| Woman | 721 (52.5) | 362 (52.8) | 359 (52.3) | — | |
|
| Gender diverse | 26 (1.9) | 13 (1.9) | 13 (0.4) | — | |
|
| .08 | |||||
|
| Western | 451 (32.8) | 225 (32.8) | 226 (32.9) | — | |
|
| East | 105 (7.7) | 40 (5.8) | 65 (9.5) | — | |
|
| Central | 813 (59.2) | 419 (61.1) | 394 (57.3) | — | |
|
| Territories | 4 (0.3) | 2 (0.3) | 2 (0.3) | — | |
|
| .43 | |||||
|
| Rural | 306 (22.3) | 159 (23.2) | 147 (21.4) | — | |
|
| Urban | 1067 (77.7) | 527 (76.8) | 540 (78.6) | — | |
|
| .05 | |||||
|
| Yes | 401 (29.2) | 217 (31.6) | 184 (26.8) | — | |
|
| No | 972 (70.8) | 469 (68.4) | 503 (73.2) | — | |
|
| .46 | |||||
|
| English | 1122 (81.7) | 561 (81.8) | 561 (81.7) | — | |
|
| French | 203 (14.8) | 105 (15.3) | 98 (14.2) | — | |
|
| Other | 48 (3.5) | 20 (2.9) | 28 (4.1) | — | |
|
| .63 | |||||
|
| Yes | 858 (62.5) | 433 (63.1) | 425 (61.9) | — | |
|
| No | 515 (37.5) | 253 (36.9) | 262 (38.1) | — | |
|
| .56 | |||||
|
| <19,999 (US $15,616.20)d | 149 (10.9) | 72 (10.5) | 77 (11.2) | — | |
|
| 20,000-39,999 (US $15,617-$31,233.20) | 253 (18.4) | 136 (19.8) | 117 (17.0) | — | |
|
| 40,000-59,999 (US $31,224-$46,850.20) | 227 (16.5) | 113 (16.5) | 114 (16.6) | — | |
|
| 60,000-79,999 (US $46,851-$62,467.20) | 217 (15.8) | 109 (15.9) | 108 (15.7) | — | |
|
| 80,000-99,999 (US $62,468-$78,084.20) | 188 (13.7) | 82 (12.0) | 106 (15.5) | — | |
|
| >100,000 (US $78,085) | 288 (21.0) | 148 (21.5) | 140 (20.4) | — | |
|
| Prefer not to answer | 51 (3.7) | 26 (3.8) | 25 (3.6) | — | |
|
| .31 | |||||
|
| North American Aboriginal | 107 (7.8) | 62 (9.0) | 45 (6.6) | — | |
|
| Other North American | 637 (46.4) | 303 (44.2) | 334 (48.6) | — | |
|
| European | 320 (23.3) | 160 (23.3) | 160 (23.3) | — | |
|
| Asian | 98 (7.1) | 51 (7.4) | 47 (6.8) | — | |
|
| Other | 211 (15.4) | 110 (16.0) | 101 (14.7) | — | |
|
| .89 | |||||
|
| Yes | 697 (50.8) | 347 (50.6) | 350 (50.9) | — | |
|
| No | 676 (49.2) | 339 (49.4) | 337 (49.1) | — | |
aChi-square or t test.
b—: not applicable.
cOf 1373 participants, 848 (61.8%) and 525 (38.2%) reported an annual income before taxes of all members of the household before the pandemic of
dAn exchange rate of CA $1=US $0.78 has been applied.
Number of participants by PAPMa vaccine intention stage and intervention group at baseline and postintervention (N=1373).
| Group | Unengaged | Undecided | Decided not | Decided to | Total | Between-group differenceb
| ||
|
| .65 | |||||||
|
| Video | 74 (10.8) | 234 (34.1) | 292 (42.6) | 86 (12.5) | 686 (50.0) | —c | |
|
| Text | 73 (10.6) | 255 (37.1) | 272 (39.6) | 87 (12.7) | 687 (50.0) | — | |
|
| .64 | |||||||
|
| Video | 54 (7.9) | 236 (34.4) | 277 (40.4) | 119 (17.3) | 686 (50.0) | — | |
|
| Text | 47 (6.8) | 249 (36.2) | 285 (41.5) | 106 (15.4) | 687 (50.0) | — | |
aPAPM: Precaution Adoption Process Model.
bChi-square test.
c—: not applicable.
Figure 2PAPM stage transitions from T1 (baseline) to T2 (postintervention) in the video group (N=686). OR: odds ratio; PAPM: Precaution Adoption Process Model. Green arrows show significant transitions toward increased and red arrows toward decreased vaccination intentions. Gray arrows show nonsignificant transitions between stages..
Figure 3PAPM stage transitions from T1 (baseline) to T2 (postintervention) in the text group (N=687). OR: odds ratio; PAPM: Precaution Adoption Process Model. Green arrows show significant transitions toward increased and red arrows toward decreased vaccination intentions. Gray arrows show nonsignificant transitions between stages.